Amgen prevails in appeal of adverse patent ruling on Sensipar

The U.S. Court of Appeals for the Federal Circuit has vacated a lower court ruling clearing Amneal Pharmaceuticals (AMRX -3.6%) of infringing on an Amgen (AMGN -0.8%) patent covering Sensipar (cinacalcet) and has sent the case back to the Delaware district court for further action.

The appeals court found that Zydus Pharmaceuticals’ generic offering infringes while Piramal Pharma Solutions’ does not.

https://seekingalpha.com/news/3530134-amgen-prevails-in-appeal-of-adverse-patent-ruling-on-sensipar